Orexigen Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Today to Discuss Acquisition of U.S. Rights to Contrave® (naltrexone HCl / bupropion HCl extended release) and Central and Eastern Europe Distribution Agreement with Valeant

15 Mar, 2016, 07:05 ET from Orexigen Therapeutics, Inc.

SAN DIEGO, March 15, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) will host a conference call this afternoon to discuss the strategic acquisition of all U.S. rights to Contrave® and the Mysimba® commercialization and distribution agreement with Valeant Pharmaceuticals International, Inc. for Central and Eastern Europe.

The call will be held today at 8:30 a.m. ET / 5:30 a.m. PT and may be accessed by phone by calling (888) 771-4371 (domestic) or (847) 585-4405 (international), participant code 42093506. The webcast can be accessed live on the Investors section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.

Orexigen Contact:

Media Contact:

McDavid Stilwell

Julie Normart

VP, Corporate Communications and Business Development


(858) 875-8629

(415) 946-1087




SOURCE Orexigen Therapeutics, Inc.